Table of Indications and Regimens from the National Cancer Control Programme, Ireland

Description:A table containing all indications published by the National Cancer Control Programme (NCCP), Ireland. Each entry has an indication code, description, and disease; regimen code, name, and URL; and information regarding whether the indication contains molecular diagnostic criteria. Entries were last updated from the NCCP website on 2025-May-27.Headings:IndicationCode: NCCP indication code (ex: 00537a).IndicationDesc: Description of the indication taken from its relevant regimen (ex: "Monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).")CancerType: Manual annotation of disease category for the indication (ex: Leukaemia).HasGeneticCriteria: Manual TRUE/FALSE annotation indicating the presence or absence of genetic criteria for the indication, as described in the indication description or regimen document.GeneticCriteria: If HasGeneticCriteria is TRUE, the relevant criteria listed (ex: BCR-ABL1 positive).HasBiomarkerCriteria: Manual TRUE/FALSE annotation indicating the presence or absence of cellular biomarker criteria for the indication, as described in the indication description or regimen document.BiomarkerCriteria: If HasBiomarkerCriteria is TRUE, the relevant criteria listed (ex: CD22+).HasMolecularCriteria: For convenience, column stating TRUE if HasBiomarkerCriteria is True or HasGeneticCriteria is True.RegimenCode: NCCP code for the regimen associated with the indication (ex: 537).RegimenName: NCCP regimen name (ex: Inotuzumab ozogamicin Monotherapy)NCCPRegimenCategories: NCCP disease categories associated with the regimen (ex: Leukaemia/BMT).RegimenURL: URL to the NCCP regimen document.Notes: Miscellaneous notes containing notes from NCCP regimen documents or further explanations.